Genomic Surveillance Reveals Emergence and Spread of Macrolide-Resistant Mycoplasma pneumoniae in Australia During the 2023–2024 Epidemic
Kingsley King-Gee Tam·Rebecca J Rockett·Louise Cooley·Indya Gardner·Michael C. Wehrhahn·Rob Baird·Varsha Sivalingam·Andrew N. Ginn·Ella M. Meumann·Enoch Tay·Karina Kennedy·Danny Ko·Thomas Tran·Lito E Papanicolas·Kerri Basile·Jennifer Robson·Winkie Fong·Maryza Graham·Sharon C-A Chen·Jen Kok·David Speers·Tanya Golubchik·Vitali Sintchenko·Carl J E Suster·Neisha Jeoffreys·Stuart Campbell·Jaimee Harbidge
Our findings demonstrate the utility of tNGS for genomic epidemiology and highlight the need for MRMP surveillance. Although macrolides remain effective in Australia, emerging MRMP strains require close monitoring to inform treatment guidelines and antimicrobial stewardship.